¼¼°èÀÇ ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : Á¦Ç° Á¾·ùº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, ±â¼úº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Drug-Device Combination Products Market, By Product Type, By Application, By End-User, By Technology, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1684325
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 383 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,590,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,568,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,980,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå ±Ô¸ð´Â 2024³â 1,394¾ï 8,942¸¸ ´Þ·¯·Î 2025³âºÎÅÍ 2032³â±îÁö CAGR 8.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå ¿ªÇÐ

ÃÖ¼Òħ½ÀÀû ¾à¹°Àü´Þ ±â±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ´ç´¢º´°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ç´¢º´, ½ÉÇ÷°üÁúȯ, È£Èí±âÁúȯ µîÀÇ À¯º´·ü Áõ°¡¿¡ µû¶ó Ä¡·á È¿°ú, ȯÀÚ ¼øÀÀµµ, ÀÇ·á Àü¹ÝÀÇ ¼º°ú¸¦ ³ôÀ̱â À§ÇØ ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç°ÀÇ È°¿ëÀÌ ´«¿¡ ¶ç°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àå±âÀûÀÎ Åõ¾à °ü¸®°¡ ÇÊ¿äÇÑ È¯ÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á È¿°ú¿Í ȯÀÚ ¼øÀÀµµ¸¦ ³ôÀ̱â À§ÇØ Àν¶¸° ÆßÇÁ, ÀÚµ¿ÁÖ»ç±â, ÇÁ¸®ÇÊµå ½Ã¸°Áö µî ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç°ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹´ç´¢º´ÇÐȸ°¡ ½Ç½ÃÇÑ ¿¬±¸¿¡ µû¸£¸é, 432°³ ´ç´¢º´ ¼¾ÅÍ¿¡¼­ 96,547¸íÀÇ 1Çü ´ç´¢º´ ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ¿¬±¸ °á°ú°¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼ú ¹ßÀü°ú ´õºÒ¾î ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø ¹× ½ÂÀÎ Áõ°¡´Â ½ÃÀå È®´ëÀÇ ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ ³ôÀº Á¦Á¶ ¹× °³¹ß ºñ¿ëÀÌ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¿¬±¸ ºÐ¼®°¡µéÀÌ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¸Å³â ¾à 8.9%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â °æÇÇ¿ë ÆÐÄ¡°¡ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¾ú½À´Ï´Ù.

¿ëµµº°·Î´Â 2024³â ½ÉÇ÷°üÀÌ ÁÖ¿ä ¿ëµµ°¡ µÇ¾ú½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î´Â º´¿øÀÌ 2024³â ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¸ÅÃâÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

¼¼°è ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀåÀº Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ªÀ» ±âÁØÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° À¯Çüº°·Î ¾à¹° ¿ëÃâ ½ºÅÙÆ®, ÁÖÀÔ ÆßÇÁ, ÈíÀÔ±â, Á¤Çü¿Ü°ú¿ë º¹ÇÕ Á¦Ç°, »óó °ü¸®¿ë º¹ÇÕ Á¦Ç°, ±¤ ¿ªÇÐ Ä¡·á ±â±â, °æÇÇ ÆÐÄ¡, Ç×±Õ Ä«Å×ÅÍ, ±âŸÀÇ 5°¡Áö ºÎ¹®À¸·Î ºÐ·ùµË´Ï´Ù. °æÇÇ ÆÐÄ¡´Â ½ÃÀå ¼ºÀåÀÇ ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ Çõ½Å¿¡ ÈûÀÔ¾î ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀåÀº Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ Áß¿äÇÑ ±¸¼º¿ä¼ÒÀÎ °æÇÇ ÆÐÄ¡´Â °æ±¸ ¹× ÁÖ»çÁ¦¿Í ºñ±³ÇÏ¿© ¾à¹° ¹æÃâÀ» ½±°Ô Á¦¾îÇϰí ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀ̸ç Àü½Å ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. Â÷¼¼´ë ÆÐÄ¡¿¡ ´ëÇÑ FDA ¹× EMAÀÇ ±ÔÁ¦ ½ÂÀÎÀº ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ýüÀûÇÕ¼º ¹× »ýºÐÇØ¼º ÆÐÄ¡ÀÇ °³¹ßÀº ÇǺΠÀÚ±ØÀ» ÁÙÀÌ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀåÀº ¿ëµµ¿¡ µû¶ó ½ÉÇ÷°ü°è, ´ç´¢º´, ¾Ï Ä¡·á, È£Èí±âÁúȯ, ±âŸÀÇ 4°¡Áö ÁÖ¿ä Ä«Å×°í¸®·Î ºÐ·ùµË´Ï´Ù. ½ÉÇ÷°ü ºÎ¹®ÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦ ½ÃÀåÀº ƯÈ÷ ½ÉÇ÷°ü°è ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÷´Ü ÃÖ¼Òħ½ÀÀû Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ½ÉÇ÷°ü°è ºÎ¹®¿¡¼­ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°µéÀº ÀǾàǰ°ú ÀÇ·á±â±â¸¦ ÅëÇÕÇÏ¿© Ä¡·á È¿°ú¸¦ Çâ»ó½Ã۰í, ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀ̸ç, ÀÔ¿ø ±â°£À» ´ÜÃà½Ãŵ´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚº°·Î º´¿ø, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ·Î ºÐ·ùµË´Ï´Ù. º´¿ø ºÐ¾ß´Â ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ºÐ¾ßÀÔ´Ï´Ù. ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀåÀº ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, º´¿øÀº ÷´Ü, È¿À²Àû, ÃÖ¼Òħ½ÀÀû Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ÀÌ·¯ÇÑ Ãß¼¼¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°µéÀº ÀǾàǰ°ú ÀÇ·á±â±â¸¦ °áÇÕÇÏ¿© Ä¡·á È¿°ú, ȯÀÚ ¼øÀÀµµ, º´¿ø ³» ¾÷¹« È¿À²¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. Á¤¹ÐÇÑ ¾à¹° Åõ¿©´Â ÁßÁõ ȯÀÚ¿¡°Ô ÇʼöÀûÀ̱⠶§¹®¿¡ º´¿øÀº ÁßÁõ ȯÀÚ Ä¡·á, ¼ö¼ú ¹× ¸¸¼ºÁúȯ °ü¸®¿¡ ÇʼöÀûÀÎ ÀÌ·¯ÇÑ Á¶ÇÕ Á¦Ç°ÀÇ ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ°¡ µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, º´¿ø¿¡¼­´Â ÃÖ¼Òħ½ÀÀû ±â¼úÀÇ µµÀÔÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¾à¹° ¿ëÃâ ½ºÅÙÆ® ¹× Ä«Å×ÅÍ ±â¹Ý ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : Áö¿ªº° ºÐ¼®

ºÏ¹Ì´Â ¼±ÁøÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó¿Í ´ë±Ô¸ð R&D Ȱµ¿À¸·Î ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº źźÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í À¯¸®ÇÑ »óȯ Á¤Ã¥ÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. 2022³â ¹Ì±¹ÀÇ ÀÇ·áºñ´Â 4.1% Áõ°¡ÇÏ¿© 4Á¶ 5,000¾ï ´Þ·¯, 1Àδç 13,493´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇÕ´Ï´Ù. ÀÌ ¼ºÀå·üÀº ¹Ì±¹ ÀÇ»çÇùȸ°¡ º¸°íÇÑ ÆÒµ¥¹Í ÀÌÀü ¼öÄ¡¿Í ÀÏÄ¡ÇÕ´Ï´Ù. ÇÑÆí, Áß±¹, ÀϺ», Àεµ µîÀÇ ±¹°¡¿¡¼­´Â ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡·Î ÀÎÇØ ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Æ¶ø¿¡¹Ì¸®Æ®¿Í ³²¾ÆÇÁ¸®Ä«°øÈ­±¹Àº ÀÇ·á ±â¼ú Çõ½Å¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Áß¿äÇÑ ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : °æÀï »óȲ

ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀåÀº °æÀïÀÌ Ä¡¿­Çϸç, ÁÖ¿ä ±â¾÷µéÀº ±â¼ú ¹ßÀü, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ ½ÃÀå ÁöÀ§¸¦ °­È­ÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. °æÀïÀÇ ¹è°æ¿¡´Â ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸¸¼ºÁúȯÀÇ È®»ê, ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. °¢ ¾÷üµéÀº ȯÀÚÀÇ ÆíÀǼº°ú Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ´Â Â÷¼¼´ë ¾à¹°°ú ±â±â Á¶ÇÕÀ» °³¹ßÇϱâ À§ÇØ °æÀïÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ÅõÀÚ Áõ°¡¿¡ µû¶ó ÁÖ¿ä ±â¾÷µéÀº ½ÅÈï ½ÃÀå(¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿)¿¡ ÁøÃâÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç°ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå »óȲ

Á¦7Àå ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : Á¦Ç° Á¾·ùº°

Á¦8Àå ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : ¿ëµµº°

Á¦9Àå ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : ÀǾàǰ-ÀÇ·á±â±â º¹ÇÕÁ¦Ç° ¾÷°è

Á¦12Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Drug Device Combination Products Market size was valued at US$ 139,489.42 Million in 2024, expanding at a CAGR of 8.9% from 2025 to 2032.

Drug-Device Combination Products represent innovative therapeutic and diagnostic solutions that integrate a pharmaceutical agent with a medical device into a unified system. These products aim to improve the efficiency of drug delivery and facilitate the controlled administration of medications. In response to the increasing demand from patients for more convenient and accessible treatment alternatives, pharmaceutical companies are progressively investing in sophisticated delivery mechanisms, including prefilled syringes, auto-injectors, and on-body injectors. Concurrently, regulatory frameworks in both the United States and the European Union are undergoing continuous development. In the United States, information about the device component of drug-led combination products is generally submitted through a singular marketing application, following the regulatory pathways for drugs or biologics, such as the Biologics License Application (BLA), New Drug Application (NDA), or Investigational New Drug (IND).

Drug-Device Combination Products Market- Market Dynamics

Increasing demand for minimally invasive drug delivery devices and increasing prevalence of chronic diseases such as diabetes are anticipated to drive the market.

As the prevalence of conditions such as diabetes, cardiovascular diseases, and respiratory disorders rises, there is a notable increase in the utilization of Drug-Device Combination Products to enhance treatment efficacy, patient compliance, and overall healthcare results. With the growing population of patients requiring long-term medication management, the use of Drug-Device Combination Products, such as insulin pumps, auto-injectors, and prefilled syringes, is on the rise to improve treatment effectiveness and patient adherence. A study conducted by the American Diabetes Association included 96,547 patients with type 1 diabetes across 432 diabetes centers. Additionally, advancements in technology, along with increasing regulatory support and approvals, may present opportunities for market expansion. Nevertheless, high manufacturing and development costs could pose challenges to market growth.

Drug-Device Combination Products Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.9% over the forecast period (2025-2032)

Based on product type segmentation, Transdermal Patches was predicted to show maximum market share in the year 2024

Based on Application segmentation, Cardiovascular was the leading Application in 2024

Based on End-User segmentation, the hospital was the leading End-User in 2024

Based on region, North America was the leading revenue generator in 2024

Drug-Device Combination Products Market- Segmentation Analysis:

The Global Drug Device Combination Products Market is segmented based on Product Type, Application, End-User, and Region.

The market is categorized into five segments according to product type: Drug Eluting Stents, Infusion Pumps, Inhalers, Orthopedic Combination Products, Wound Care Combination Products, Photodynamic Therapy Devices, Transdermal Patches, Antimicrobial Catheters, and Others. Transdermal Patches are at the forefront of market growth. The Drug-Device Combination Products Market is witnessing significant expansion, propelled by innovations in transdermal drug delivery systems. Transdermal patches, a vital component of this sector, facilitate controlled drug release, enhance patient adherence, and mitigate systemic side effects when compared to oral or injectable options. Regulatory approvals from the FDA and EMA for next-generation patches are contributing to market growth. Additionally, the development of biocompatible and biodegradable patches aims to reduce skin irritation.

The market is classified into four primary categories based on application: Cardiovascular, Diabetes, Cancer Treatment, Respiratory Diseases, and Other. The Cardiovascular segment leads the market. The Drug-Device Combination Products Market is experiencing substantial growth, especially within the cardiovascular segment, driven by the rising incidence of heart diseases and the growing need for sophisticated, minimally invasive treatment options. These products integrate pharmaceuticals with medical devices to improve therapeutic results, enhance patient adherence, and shorten hospital stays.

The market is categorized into two segments based on End-User: Hospitals, Ambulatory Surgical Centers, and Others. The hospital segment is the leading sector within this market. The Drug-Device Combination Products Market is experiencing rapid growth, with hospitals significantly contributing to this trend due to the increasing demand for advanced, efficient, and minimally invasive treatment options. These products combine pharmaceuticals with medical devices, thereby improving therapeutic effectiveness, patient adherence, and operational efficiency within hospital settings. High-precision drug administration is essential for patients in critical care, making hospitals the primary end-users of these combination products, which are vital for critical care, surgical procedures, and the management of chronic diseases. Furthermore, hospitals are increasingly adopting minimally invasive techniques, which has led to a rise in the use of drug-eluting stents and catheter-based drug delivery systems.

Drug Device Combination Products Market- Geographical Insights

North America leads in market growth, attributed to its advanced healthcare infrastructure and significant research and development activities. The region benefits from a robust regulatory framework and advantageous reimbursement policies, which further facilitate market growth. In 2022, health expenditures in the United States rose by 4.1%, reaching USD 4.5 trillion, or USD 13,493 per capita. This growth rate aligns with pre-pandemic figures, as reported by the American Medical Association. Meanwhile, countries such as China, Japan, and India are witnessing a growing demand for drug-device combination products, driven by the rising incidence of chronic diseases. Additionally, the UAE and South Africa represent important markets due to their increased investments in medical innovation.

Drug-Device Combination Products Market- Competitive Landscape:

The Drug-Device Combination Products Market is highly competitive, with key players focusing on technological advancements, regulatory approvals, and strategic collaborations to strengthen their market position. The competition is driven by the rising demand for advanced drug delivery systems, the increasing prevalence of chronic diseases, and the growing preference for minimally invasive treatments. Companies compete by developing next-generation drug-device combinations that enhance patient convenience and therapeutic efficacy. Major companies are expanding into emerging markets (Asia-Pacific, Latin America, and the Middle East) due to increasing healthcare investments.

Recent Developments:

In May 2024, Novartis announced that it had reached an agreement to acquire Mariana Oncology, a biotechnology firm in the preclinical stage located in Watertown, Massachusetts. The company specializes in the development of innovative radio ligand therapies (RLTs) aimed at addressing cancers that present significant unmet medical needs.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DRUG DEVICE COMBINATION PRODUCTS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Drug Device Combination Products Market Overview

2. Executive Summary

3. Drug Device Combination Products Key Market Trends

4. Drug Device Combination Products Industry Study

5. Drug Device Combination Products Market: Impact of Escalating Geopolitical Tensions

6. Drug Device Combination Products Market Landscape

7. Drug Device Combination Products Market - By Product Type

8. Drug Device Combination Products Market - By Application

9. Drug Device Combination Products Market - By End-User

10. Drug Device Combination Products Market- By Geography

11. Key Vendor Analysis- Drug Device Combination Products Industry

12. 360 Degree AnalystView

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â